Pharmacogenetics of oral anticoagulants

Pharmacogenetics

Volumn 13, Issue 5, 2003, Pages 247-252

  Daly, Ann K ^a   King, Barry P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CYP2C9; Cytochrome P450; Genotype; Oral anticoagulant; Polymorphism

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; CYTOCHROME P450; CYTOCHROME P450 2C9; OXIDOREDUCTASE; PHENPROCOUMON; VITAMIN K GROUP; WARFARIN;

AEROBIC METABOLISM; ALLELE; BLEEDING; CATALYSIS; DRUG RESISTANCE; ENANTIOMER; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 0037565623     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200305000-00002     Document Type: Short Survey

References (42)

1. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40:587-603.
2. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73:67-74.
3. Hermans JJR, Thijssen HHW. Stereoselective acetonyl side chain reduction of warfarin and analogs - partial characterization of two cytosolic carbonyl reductases. Drug Metab Dispos 1992; 20:268-274.
4. He MX, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372:16-28.
5. Thijssen HH, Flinois J-P, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28:1284-1290.
6. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Geldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11:803-808.
7. Goldstein JA. Polymorphisms in the human CYP2C subfamily. Drug Metab Rev 2002; 34:5.
8. Higashi MK, Veenstra DL, Kondo LML, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002; 287:1690-1698.
9. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
10. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52:447-450.
11. Xie H-G, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Metab Rev 2002; 54:1257-1270.
12. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
13. Crespi CL, Miller VP. The R144C change in the CYP2C9* 2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7:203-210.
14. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
15. Leung AYH, Chow HCH, Kwong YL, Lie AKW, Fung ATK, Chow WH, et al. Genetic polymorphism in exon 4 of cytochrome P450CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98:2584-2587.
16. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin Pharmacol Ther 2001; 70:175-182.
17. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125:803-808.
18. Sachse C, Brechmoller J, Bauer S, Roots I. Functional significance of a C>A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47:445-449.
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 27:383-391.
20. Aithal GP, Day CP, Kesteven PJL, Daly AK. Warfarin dose requirement and CYP2C9 polymorphisms - reply. Lancet 1999; 353:1972-1973.
21. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 2001; 70:159-164.
22. Furuya H, Fernandez Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anti-coagulation therapy. Pharmacogenetics 1995; 5:389-392.
23. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-367.
24. Ogg MS, Brennan P, Meade T, Humphries SE. CYP2C9*3 allelic variant and bleeding complications [Comment]. Lancet 1999; 354:1124.
25. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96:1816-1819.
26. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Clampa A, Grandone E, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775-778.
27. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002; 194:267-273.
28. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72:702-710.
29. Baglin T. Avoiding overanticoagulation: pharmacogenomics or pragmatism? Thromb Haemost 2001; 85:945-946.
30. Thijssen HHW, Verkooijen IWC, Frank HLL. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics 2000; 10:757-760.
31. Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, et al. Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers. Pharmacogenetics 2001; 11:735-737.
32. Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450CYP2C9 on sensitivity to acenocournarol. Blood 2002; 99: 4237-4239.
33. Tassies D, Freire C, Puoan J, Maragall S, Monteagudo J, Ordinas A, et al. Pharmacogenetics of acenocoumarol: cytochrome P450CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87:1185-1191.
34. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128:281-285.
35. Yasar U, Oscarson M, Eliasson E, Sjoqvist F. Mutations of the CYP2C9 gene and the response to warfarin [Comment]. Surgery 2001; 129:384.
36. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. New Engl J Med 1970; 282:1448-1451.
37. Hallak HO, Wedlund PJ, Modi MW, Patel IH, Lewis GL, Woodruff B, et al. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993; 35:327-330.
38. Cain D, Hutson SM, Wallin R. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. Thromb Haemost 1998; 80:128-133.
39. Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J 2001; 15:U163-U186.
40. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 2000; 96:1996-1998.
41. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochreme P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20:342-349.
42. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty - a randomized, double-blind trial. Ann Intern Med 2002; 137:648-655.